Telomerase: After the entusiasm

Technology Briefing

The cloning of a human catalytic subunit of the enzyme telomerase, which is responsible for maintaining chromosome ends long enough for cell division to continue, sent Geron Corp.'s stock soaring 111 percent last week, but the surge may reflect a lack of investor perspective. In context, the cloning is a positive step towards understanding cell senescence and cancer, but GERN is a long way from a compound entering the clinic.

The cloning was reported by GERN and the University of Colorado in Science and by MIT and Merck Research Labs in

Read the full 938 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE